FONT-SIZE Plus   Neg

Santarus Says FDA Accepts Application Seeking Approval For Colon Drug Uceris

Biopharmaceutical company Santarus, Inc. (SNTS) on Wednesday said the United States Food and Drug Administration has accepted for filing its new drug application for Uceris tablets indicated for treatment of inflammatory bowel disease.

With the application, or NDA, the company seeks approval to market Uceris (budesonide) tablets 9 mg in the U.S. as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review or a response to the NDA by mid-October 2012.

Santarus will now pay $4 million to the co-developer of the drug, Cosmo Technologies Limited, a unit of Japan's Cosmo Pharmaceuticals S.p.A, in cash or Santarus stock at Cosmo's option.

Ulcerative colitis is a form of inflammatory bowel disease that produces inflammation and ulcers along the inside of the colon that could cause cramping, bloating, diarrhea, bleeding, fatigue, weight loss and frequent bowel movements. According to the Crohn's & Colitis Foundation of America, the chronic relapsing-remitting illness affects an estimated 1.4 million Americans.

Gerald Proehl, president and chief executive officer, stated, "Ulcerative colitis is a serious, chronic disease that typically starts to manifest in young adults with a long-term negative impact on the patient. We look forward to the potential to offer what we believe will be an important new therapeutic option to physicians and their patients to manage the symptoms of active ulcerative colitis."

Santarus shares closed Tuesday's regular trading session at $4.80, down $0.12 or 2.44 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Boeing Co. (BA) reported a profit for the third-quarter climbed 34 percent from the the previous year, reflecting overall solid execution on production programs and services, favorable tax items, and timing of aircraft deliveries. The company raised its 2016 financial and delivery guidance reflecting higher commercial deliveries and the impact of the tax basis adjustment. GlaxoSmithKline PLC (GSK.L, GSK) reported that its third-quarter core operating profit was 2.32 billion pounds, 13% higher in CER terms than in prior year. Core earnings per share for the quarter was up 12% CER to 32.0 pence. Total basic earnings per share was 16.6 pence, down 1% CER, primarily reflecting... Coca-Cola Co. (KO) reported a profit for the third-quarter that declined 28 percent from the prior year. Net revenues were down 7% from prior year, impacted by a foreign currency exchange headwind of 2% and a headwind from acquisitions, divestitures and structural items of 8%. The company reaffirmed organic revenue and comparable earnings per share outlook for fiscal year 2016.
comments powered by Disqus
Follow RTT